2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026)
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026)
The 2ⁿᵈ Edition of the World Vaccines R&D Conference (WVRDC 2026) will convene leading scientists, researchers, healthcare professionals, and industry innovators to advance global vaccine research, development, and public health strategies. Hosted by Precision Global Conferences, this event builds on the success of the 2025 edition, fostering collaboration across academia, government, and the pharmaceutical sector to address emerging challenges in immunology, vaccine technology, and disease prevention.
Event Overview
As part of Precision Global Conferences’ portfolio of international scientific events, WVRDC 2026 will focus on cutting-edge advancements in vaccine science, including mRNA technologies, pandemic preparedness, personalized immunotherapies, and ethical considerations in global vaccine distribution. The conference aims to bridge gaps between research and real-world application, ensuring equitable access to life-saving vaccines worldwide.
Key Highlights
- Scientific sessions on next-generation vaccine platforms and delivery systems
- Discussions on regulatory frameworks and clinical trial innovations
- Exhibition of technologies for vaccine manufacturing and supply chain optimization
- Networking opportunities with global stakeholders in immunology and public health
- Workshops on vaccine hesitancy, epidemiology, and data-driven health policies
Target Audience
- Academic researchers in immunology and microbiology
- Pharmaceutical and biotech industry professionals
- Public health officials and policymakers
- Clinical trial coordinators and regulatory affairs specialists
- Professors, postdoctoral fellows, and graduate students in vaccine-related fields
Why Attend?
WVRDC 2026 offers a unique platform to present groundbreaking research, collaborate with global experts, and stay updated on the latest trends in vaccine development. With a focus on interdisciplinary dialogue, the conference will equip attendees with actionable insights to accelerate the translation of scientific discoveries into tangible health benefits.
*Note: Specific dates, venue, and location details for WVRDC 2026 will be updated on the official Precision Global Conferences website as they become available. For inquiries, contact info@precisionglobalconferences.com.*
Data sheet
2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026) – Event Attendee & Buyer Profile Analysis
Event date: 21 September 2026 – 23 September 2026
Location: Miami, Florida, USA
Event status: Upcoming
Research date: 30 June 2026
Event Overview
| Event Name | 2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026) |
| Event Date | 21 September 2026 – 23 September 2026 |
| Event Status | Upcoming |
| Venue | Not publicly confirmed by the organizer at the time of research. |
| City | Miami |
| State / Region | Florida |
| Country | USA |
| Organizer | Precision Global Conferences |
| Official Event Website | precisionglobalconferences.com |
| Event Type | International scientific conference with research, clinical, industry, and networking components |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research |
| Audience Reach | Likely international / global, based on organizer positioning as an international scientific events platform and the vaccine R&D subject matter |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for headcount; organizer identity and event branding confirmed, but venue and public attendance metrics were not published in the source set reviewed. |
| Main Purpose of Event | To convene vaccine researchers, pharma and biotech leaders, clinicians, public health stakeholders, and technology providers around vaccine discovery, development, manufacturing, regulation, delivery systems, and pandemic preparedness. |
About the Event
The 2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026) is positioned as a specialist scientific and industry forum focused on vaccine research, development, immunology, manufacturing innovation, and public health application. Based on the organizer’s published description, the program is expected to cover next-generation vaccine platforms, mRNA technologies, clinical and regulatory considerations, pandemic preparedness, supply chain optimization, and equitable vaccine access.
From a commercial and attendee-intelligence perspective, this event matters because it can attract a high-value mix of vaccine developers, translational researchers, biotech executives, clinical development leaders, regulatory specialists, manufacturing teams, public health organizations, and partnership-oriented business development professionals. Even where public attendee rosters are not yet disclosed, the event theme strongly aligns with buyer-side audiences involved in R&D collaborations, manufacturing scale-up, technology sourcing, trial operations, scientific partnerships, and government or nonprofit health initiatives.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Vaccine R&D leadership | Pharma vaccine divisions, biotech vaccine developers, translational research institutes | Defines platform strategy, evaluates technologies, selects collaborators | High relevance for platform technologies, adjuvants, delivery systems, analytics, and partner discovery |
| Clinical development and trial operations | Biopharma clinical teams, CRO-connected sponsor teams, academic clinical units | Influences study design, vendor selection, trial execution, and site strategy | Relevant for CRO services, eClinical tools, patient recruitment, biostatistics, and safety systems |
| Manufacturing and process development teams | Vaccine manufacturers, CDMOs, biologics production organizations | Sources process equipment, raw materials, quality systems, and scale-up support | Strong fit for single-use systems, fill-finish, formulation, cold-chain, QA/QC, and automation suppliers |
| Regulatory and quality leaders | Pharma, biotech, public health labs, compliance consultancies | Shapes compliance pathways, documentation, validation, and inspection readiness | Relevant for regulatory software, validation, quality management, and advisory services |
| Government and public health stakeholders | Health agencies, biomedical funding bodies, preparedness programs, immunization authorities | Influences grant allocation, procurement frameworks, emergency preparedness, and partnerships | Important for diagnostics, preparedness tools, surveillance, and public-private partnership providers |
| Business development and alliance managers | Pharma, biotech, platform companies, licensing groups | Evaluates licensing, co-development, distribution, and strategic collaboration opportunities | Strong fit for partnering outreach, co-marketing, CDMO introductions, and deal sourcing |
| Academic and research scientists | Universities, medical schools, research hospitals, immunology centers | Influences pilot studies, publications, translational partnerships, and grant-backed purchases | Relevant for laboratory platforms, sequencing, reagents, analytics, and collaboration services |
| Supply chain and cold-chain leaders | Manufacturers, distributors, global health organizations, specialty logistics firms | Sources packaging, tracking, temperature-control, and distribution support | Relevant for packaging, serialization, cold-chain monitoring, and transport solutions |
| Investors and health innovation advisors | Life sciences investors, innovation groups, strategic advisors | Assesses pipeline strength, platform differentiation, and partnership-readiness | Useful for scouting technology, portfolio companies, and commercialization prospects |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Miami | Local hospitals, universities, biotech professionals, health innovation ecosystem participants | Medium | Host-city access supports attendance from South Florida healthcare and life sciences networks. |
| Florida | Statewide academic medical centers, public health entities, biotech firms, contract research and manufacturing contacts | Medium to High | Florida contributes regional life sciences, healthcare, and clinical research attendance. |
| U.S. East Coast and Southeast | Attendees from pharma, biotech, public health, and university research hubs | High | Likely draw from major biomedical corridors due accessible air travel and conference focus. |
| National U.S. | Biopharma companies, federal health stakeholders, clinical and regulatory teams, CROs, CDMOs | High | Vaccine R&D is a specialized national market with concentrated enterprise and government participation. |
| International | Global researchers, vaccine developers, NGOs, and public health experts | High | Organizer branding and vaccine topic indicate likely cross-border participation, especially from Europe, North America, and global health networks. |
| Latin America and Caribbean corridor | Regional health systems, import/distribution stakeholders, research institutions, public health agencies | Medium | Miami can serve as a regional access point for cross-border scientific and healthcare business travel. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The organizer positions itself as an international conference company, and vaccine R&D is inherently cross-border across pharma, biotech, public health, and academia. |
| National | Secondary practical reach | The U.S. market remains central for vaccine research, regulation, development partnerships, and federal health participation. |
4. Sample Buyer Companies and Websites
No official current-year attendee, buyer, exhibitor, or speaker organization list was publicly identified in the reviewed source set. The table below is therefore a prospecting-oriented list of high-fit buyer-side organizations relevant to the event theme. These organizations are not confirmed attendees for WVRDC 2026.
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Moderna | Vaccine developer / biotech buyer | Strong fit for mRNA, clinical development, manufacturing, and platform collaboration topics | modernatx.com | VP Vaccines, Director Clinical Development, Director External Innovation, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| Pfizer | Global pharma vaccine buyer | Relevant for vaccine R&D, manufacturing, global access, and strategic sourcing | pfizer.com | VP Vaccines, Director R&D Partnerships, Global Procurement Director, CMC Leader | Strong Market Fit, Attendance Not Confirmed |
| GSK | Global vaccine manufacturer | Major vaccine portfolio and active buyer of R&D, process, and clinical capabilities | gsk.com | Head of Vaccines R&D, Strategic Sourcing Director, Alliance Director, Manufacturing Director | Strong Market Fit, Attendance Not Confirmed |
| Sanofi | Global vaccine developer | Relevant for immunization, manufacturing scale, clinical programs, and supply partnerships | sanofi.com | Global Vaccine Partnerships Lead, Procurement Director, Clinical Operations Director | Strong Market Fit, Attendance Not Confirmed |
| Merck | Pharma vaccine buyer | Important vaccine research and commercial organization with sourcing and partnership activity | merck.com | Associate VP Vaccines, Director Strategic Sourcing, Director Process Development | Strong Market Fit, Attendance Not Confirmed |
| CSL Seqirus | Vaccine manufacturer | Strong fit for influenza, manufacturing, pandemic preparedness, and supply chain topics | seqirus.com | Head of Manufacturing, Procurement Lead, R&D Director, Supply Chain Director | Strong Market Fit, Attendance Not Confirmed |
| Bavarian Nordic | Specialty vaccine company | Relevant for infectious disease, platform innovation, and government-linked vaccine programs | bavarian-nordic.com | Business Development Director, Clinical Development Lead, CMC Director | Strong Market Fit, Attendance Not Confirmed |
| Novavax | Vaccine biotech | Relevant for adjuvant systems, manufacturing, clinical, and commercialization support needs | novavax.com | VP Technical Operations, Strategic Sourcing Manager, Alliance Management Director | Strong Market Fit, Attendance Not Confirmed |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government / research funding stakeholder | Relevant for infectious disease vaccine science, grants, and translational research partnerships | niaid.nih.gov | Program Officer, Scientific Director, Clinical Program Lead, Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| Biomedical Advanced Research and Development Authority (BARDA) | Government preparedness and procurement stakeholder | Strong fit for pandemic preparedness, advanced development, and public-private vaccine initiatives | medicalcountermeasures.gov | Program Manager, Contracting Officer, Partnerships Lead, Portfolio Director | Strong Market Fit, Attendance Not Confirmed |
| Centers for Disease Control and Prevention (CDC) | Public health stakeholder | Relevant for immunization strategy, epidemiology, disease prevention, and public health implementation | cdc.gov | Immunization Program Director, Scientific Advisor, Public Health Program Manager | Strong Market Fit, Attendance Not Confirmed |
| Coalition for Epidemic Preparedness Innovations (CEPI) | Global health funding and partnership organization | Relevant for vaccine preparedness, equitable access, and cross-border development initiatives | cepi.net | Program Director, Vaccine Portfolio Lead, Partnerships Director | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | VP / Head of Vaccines R&D | Research & Development | VP, Executive | Owns scientific strategy and evaluates enabling technologies and partnerships. |
| 2 | Director of Clinical Development | Clinical | Director | Influences trials, vendor selection, and operational partnerships. |
| 3 | Director of Process Development / CMC | Manufacturing / Technical Operations | Director | Key for scale-up, formulation, manufacturing systems, and quality readiness. |
| 4 | Strategic Sourcing Manager | Procurement | Manager | Directly relevant for supplier onboarding, category evaluation, and budgeted purchasing. |
| 5 | Director of Procurement | Procurement | Director | Owns sourcing strategy for manufacturing, lab, and outsourced service spend. |
| 6 | Alliance / Partnerships Director | Business Development | Director | Critical for licensing, co-development, platform access, and partner screening. |
| 7 | Head of Regulatory Affairs | Regulatory | Director, VP | Influences compliance systems, submissions, validation, and advisory spending. |
| 8 | Supply Chain Director | Supply Chain / Operations | Director | Relevant for cold-chain, distribution, packaging, and continuity planning. |
| 9 | Program Manager, Biomedical Preparedness | Government / Public Health | Manager, Director | Important for grant-backed projects, government partnerships, and emergency response programs. |
| 10 | Principal Investigator / Research Professor | Academic Research | Senior Individual Contributor, Director | Can influence early-stage technology adoption, collaborations, and funded lab purchases. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Core fit for vaccine innovation, platform science, and pipeline development | Platform partnerships, lab tools, clinical vendors |
| 2 | Pharmaceuticals | Major vaccine sponsors and enterprise buyers sit here | Procurement, manufacturing, R&D collaborations |
| 3 | Research | Academic institutes and specialized scientific centers are highly relevant | Grant-funded tools, research partnerships |
| 4 | Hospital & Health Care | Clinical trial sites, translational hospitals, immunization stakeholders | Clinical programs, hospital research collaboration |
| 5 | Medical Devices | Relevant for delivery systems, injection tech, cold-chain monitoring, and trial devices | Device-enabled vaccine administration and monitoring |
| 6 | Government Administration | Public health and preparedness agencies influence funding and procurement | Programs, grants, public sector outreach |
| 7 | International Trade & Development | Useful for global vaccine access and cross-border health implementation groups | NGO and development partnerships |
| 8 | Information Technology & Services | Supports clinical, regulatory, data, and lab informatics use cases | eClinical, analytics, compliance software |
| 9 | Logistics & Supply Chain | Cold-chain and distribution matter for vaccine delivery | Packaging, transport, chain-of-custody solutions |
| 10 | Health, Wellness & Fitness | Broader preventive health ecosystem and immunization programs | Population health and prevention outreach |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | No public attendance figure found in reviewed source set | No reliable current-year headcount published. |
| Exhibitor count | Not publicly confirmed | Unconfirmed | No exhibitor list identified | Conference may feature sponsors or table-top participation, but data was not published. |
| Buyer count | Not publicly confirmed | Unconfirmed | No attendee profile statistics published | Buyer-side audience inferred from event theme only. |
| Speaker count | Not publicly confirmed | Unconfirmed | Public speaker agenda not identified | Speaker roster may be announced closer to event. |
| Sponsor count | Not publicly confirmed | Unconfirmed | No sponsor directory identified | Commercial participation likely, but not officially quantified. |
| Historical attendance | No verified prior-year attendance figure identified | Historical data unavailable | Reviewed source excerpt did not include 2025 attendance metrics | Use caution in forecasting scale until organizer publishes statistics. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Vaccine discovery and immunology | New targets, antigen design, immune profiling | Connect with R&D heads and principal investigators | Research platforms, analytics, assay tools, bioinformatics |
| mRNA and next-generation platforms | Platform optimization, delivery systems, formulation support | Target innovation, process, and alliance teams | LNP delivery, platform engineering, IP licensing, reagents |
| Clinical trial innovation | Faster enrollment, site management, safety data capture | Engage clinical ops and medical affairs leaders | CRO services, eClinical, biostatistics, recruitment tools |
| Regulatory frameworks | Submission readiness, validation, quality systems | Approach regulatory and QA decision makers | Regulatory consulting, QMS software, compliance support |
| Manufacturing and scale-up | Reliable production, fill-finish, process consistency | Meet technical operations and procurement leaders | CDMO services, single-use systems, process automation, QA/QC tools |
| Cold-chain and supply chain optimization | Temperature assurance, packaging, global distribution | Target supply chain and operations buyers | Cold storage, data loggers, packaging, specialty logistics |
| Pandemic preparedness | Rapid response, strategic partnerships, preparedness planning | Engage government, NGO, and enterprise preparedness programs | Preparedness solutions, advanced development support, surveillance tools |
| Global vaccine access and ethics | Distribution equity, partnerships, implementation strategy | Engage global health organizations and public policy stakeholders | Deployment models, access frameworks, regional commercialization partners |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | Subject matter is specialized and aligned with budget-owning life sciences, public health, and research buyers. |
| Decision-maker availability | Medium to High | Scientific conferences often attract directors, principal investigators, R&D heads, and partnerships leaders, though not all are direct procurement signatories. |
| Data collection potential | Medium | Good for title-based lead capture and partnership outreach, but public attendee transparency is currently limited. |
| Apollo targeting potential | High | Well-suited to industry, function, title, and account-based targeting across vaccine, biotech, and public health ecosystems. |
| Geographic targeting potential | High | Can be targeted across the U.S., Europe, and international life sciences clusters. |
| Best outreach approach | High | Use scientific-value messaging, partnership positioning, and role-specific pain points rather than generic event sales outreach. |
| Overall lead quality | High | Best for high-value B2B, scientific alliances, vendor partnerships, and specialized life sciences solution selling. |
| Best use case | High | ABM prospecting, speaker-org targeting, pharma/biotech partner mapping, and public health stakeholder outreach. |
| Limitations / risks | Medium | Venue, attendance scale, and official participant lists are not yet public, limiting confirmed event-intelligence precision. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Research; Hospital & Health Care; Medical Devices; Government Administration; International Trade & Development; Information Technology & Services; Logistics & Supply Chain | Focus on the most relevant vaccine, clinical, public health, and enabling technology accounts. |
| Departments | Research, Clinical, Operations, Procurement, Supply Chain, Business Development, Regulatory Affairs, Quality, Partnerships | Match outreach to budget owners and technical influencers. |
| Seniority | Director, VP, CXO, Head, Manager, Principal | Capture both strategic decision makers and operational evaluators. |
| Job titles | Head of Vaccines R&D; VP Vaccines; Director Clinical Development; Director Process Development; CMC Director; Director Procurement; Strategic Sourcing Manager; Alliance Director; Partnerships Director; Regulatory Affairs Director; Supply Chain Director; Program Manager Immunization | Supports account-based outreach around relevant vaccine workflows. |
| Geography | United States; Canada; United Kingdom; Germany; Switzerland; Belgium; France; Netherlands; Singapore; selected global health organizations | Aligns with likely high-value vaccine and biotech clusters. |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Covers scaling biotech through major enterprise pharma and public-sector institutions. |
| Keywords | vaccine, immunology, mRNA, biologics, infectious disease, adjuvant, clinical trials, CMC, fill-finish, cold chain, pandemic preparedness, immunization | Refines account and contact selection to conference-relevant themes. |
| Technologies, if relevant | eClinical systems, lab informatics, quality systems, cold-chain monitoring, bioprocessing tools | Useful when targeting solution-specific buyer groups. |
| Revenue range, if relevant | $10M–$50M; $50M–$500M; $500M+ | Helps separate venture-stage biotech from enterprise vaccine manufacturers. |
| Company type | Public; Private; Government; Nonprofit; Academic / Research Institution | Important because buyer behavior differs across commercial and public health entities. |
Suggested Apollo Search Logic: ("vaccine" OR "vaccines" OR immunology OR mRNA OR biologics OR "infectious disease" OR immunization OR adjuvant OR "pandemic preparedness") AND (R&D OR clinical OR CMC OR manufacturing OR procurement OR partnerships OR regulatory OR supply chain).
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| Precision Global Conferences | Official organizer website | Organizer identity, international scientific conference positioning, existence of World Vaccines R&D Conference in organizer portfolio, and 2026 conference programming context | High |
| Official website content excerpt provided by user | Primary-source text supplied for review | Confirmed that the organizer lists “World Vaccines R&D Conference” within its conference portfolio; no venue or attendance figure was present in the supplied text | High for listed facts; limited for unpublished details |
| User-supplied event details | Provided event metadata | Miami, Florida, USA and dates of 21–23 September 2026 | Medium pending direct publication on official event page |
Suitability for B2B attendee list building: Moderately suitable at this stage. The event theme is commercially valuable for life sciences targeting, but official public participant data is currently limited. Best near-term use is account-based prospecting against vaccine, biotech, public health, and research organizations rather than claiming confirmed attendee coverage.
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2ⁿᵈ Edition of World Vaccines R&D Conference (WVRDC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds